本文介绍目前市面上已经获批或者在研的几款anti-HER2 ADC药物的载药信息和对ADC药物性质的影响,包括DS-8201、SYD985、RC-48、T-DM1、ARX788。 图1. ADC药物的作用机制24 ADC药物载药的结构和机制特点 ADC所携带的细胞毒性载荷药物是其最重要的效应成分,...
而将非结合对照ADC与曲妥珠单抗或培妥单抗联合给药后,活性很低。 活性的提高可能是由于与非重叠表位结合或Fc受体聚集增加了内化。 总结 XMT-2056靶向HER2的差异性表位,在联合应用中发挥出1+1>2的效果,同时利用STING 激动剂诱导Ⅰ型干扰...
ADC-W-212 Anti-HER2-MODO ADC Humanized Anti-ERBB2 lgG1 antibody MODO (monomethyldolastatin) Inquiry ADC-W-242 Anti-ERBB2 (Trastuzumab-HC-K121)-DBCO-MMAF ADC Humanized Anti-ERBB2 IgG1 Antibody, Trastuzumab variant, HC-K121 DBCO (Dibenzocyclooctyl) MMAF (Monomethyl auristatin F) Inquiry ADC...
Anti-HER2-ADC bei Brustkrebsdoi:10.1007/s15004-019-7256-8RedaktionSpringerOnkologieSpringerInFo Hmatologie + Onkologie
ESMO Breast Cancer Annual Meeting Lebensqualität unter Anti-HER2-ADC Auf dem Breast Cancer Annual Meeting der European Society for Medical Oncology (ESMO) wurden unter anderem neue Daten zur gegen HER-gerichteten Therapie mit dem Antikörper- Wirkstoff-Konjugat (ADC) Trastuzumab-Deruxtecan ...
(21) 对研究过程可能用到的清淋药物或对症处理 CRS 的药物过敏或不耐受的患者,包括但不限于氟达拉滨和环磷酰胺或托珠单抗;已知对 anti-HER2-CAR-T 的成分过敏;或有任何严重的过敏史,例如,过敏性休克; (22) 给药前1个月内参加过其他干预性临床试验者; ...
Metastatic HER2 + breast cancer is an expanding area of drug development and research, with three new drugs approved in 2020 alone. While first-line therapy is well-established for metastatic HER2 + breast cancer, the standard of care for second-line therapy will likely be changing soo...
Moreover, our proposed ADC linker technology can be implemented in additional medical conditions such as other malignancies as well as autoimmune diseases that overexpress targets, other than HER2.Cancer researchYulia LiubomirskiGalia TiramAnna ScomparinSamer GnaimSayantan DasSachin GholapLiang GeEilam Ye...
By targeting dual tumor-associated antigens (TAA), the bispecific ADC (BsADC) serves as a promising therapeutic strategy that can further increase tissue specificity and selectivity. HER2 and TROP2 are two TAAs that are commonly expressed and co-expressed by multiple tumor types, including gastric...
Similar results on HER237 and TF38 (tissue factor) specific antibody-drug conjugates (ADC) have been reported by comparing the ADC efficacy on cultured cells in IgG and Fab form. However, the data also suggest that the bivalent enhancement of immunotoxin cytotoxicity is antibody-dependent, i.e...